Specialty pharmaceutical company iX Biopharma (“iX Biopharma” or “the Group”) will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine.
Singapore, 5 November 2018 – Specialty pharmaceutical company iX Biopharma (“iX Biopharma” or “the Group”) will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark. Dr Janakan Krishnarajah, iX Biopharma’s Chief Medical Officer, will be presenting the results on 6 November 2018 at 3:00pm (GMT+1).
Bio-Europe is Europe’s largest annual life science partnering conference. The conference facilitates new partnerships by allowing companies to present themselves and identify business and licensing opportunities. It is attended by approximately 2,000 companies and 4,000 business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts from all around the world.
The Bio-Europe conference gives iX Biopharma an opportunity and platform to identify suitable prospective partners for its range of products and the WaferiX sublingual delivery technology. Through the partnering program, iX Biopharma has received very strong interest for Wafermine and the WaferiX technology.
The presentation slides can be accessed at SGXNET and www.ixbiopharma.com starting from 9:00a.m. (GMT +8) on 7 November 2018.
